Loading…
Quince Therapeutics, Inc. is projected to decline to $1.04 by 2027, a -9% move from its current price of $1.15. QNCX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.07 | $1.15 | $1.23 | +0.04% |
| May 30 | $1.05 | $1.15 | $1.27 | +0.08% |
| May 31 | $1.02 | $1.15 | $1.30 | +0.11% |
| Jun 1 | $1.01 | $1.15 | $1.32 | +0.15% |
| Jun 2 | $0.9896 | $1.15 | $1.34 | +0.19% |
| Jun 3 | $0.9758 | $1.15 | $1.36 | +0.23% |
| Jun 4 | $0.9632 | $1.15 | $1.38 | +0.27% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.9632 | $1.15 | $1.38 | +0.27% |
| Week 2 | $0.8964 | $1.16 | $1.49 | +0.53% |
| Week 3 | $0.8488 | $1.16 | $1.58 | +0.80% |
| Week 4 | $0.811 | $1.16 | $1.67 | +1.07% |
| Week 5 | $0.7794 | $1.17 | $1.74 | +1.34% |
| Week 6 | $0.752 | $1.17 | $1.82 | +1.61% |
| Week 7 | $0.7279 | $1.17 | $1.89 | +1.88% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Quince Therapeutics, Inc. is a biotechnology company focused on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases.
Its lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.
Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consist of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc.
in August 2022. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
The current price of Quince Therapeutics, Inc. (QNCX) is $1.10. The company has a market capitalization of $21.52M and ranks 4919 by market cap.
Forecasts imply upside potential over the long run, with a path from the current level toward higher values. The 2026 forecast shows an average price of $1.10 and a maximum of $1.46, while the 2030 forecast projects an average of $1.45 and a maximum of $2.53. By 2050, the forecast envisions an average price of $3.65 with a maximum of $8.39, indicating meaningful long‑term upside.
A major floor 30.7% below — a decisive break under it would weaken the trend.
The nearest floor, 13.5% below — buyers have tended to step in here.
The nearest ceiling, 19.1% above — a clean break opens room to run.
A major ceiling 2987.0% above — clearing it would confirm fresh momentum.
Key QNCX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of QNCX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.12 | Buy | $1.14 | Buy |
| MA 10 | $1.12 | Buy | $1.14 | Buy |
| MA 20 | $1.19 | Sell | $1.18 | Sell |
| MA 50 | $1.18 | Sell | $2.31 | Sell |
| MA 100 | $6.61 | Sell | $6.14 | Sell |
| MA 200 | $14.27 | Sell | $10.39 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.15 | Neutral |
| Stoch RSI (14) | 80.59 | Sell |
| CCI (20) | -37.66 | Neutral |
| Williams %R (14) | -49.18 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | -10.16 | Sell |
| Bollinger %B (20,2) | 0.38 | Neutral |
| Stochastic %K (14) | 50.82 | Neutral |
| TRIX (15) | -0.66 | Sell |
| Awesome (5,34) | -0.12 | Sell |
| Ultimate (7,14,28) | 47.53 | Neutral |
| Momentum (10) | -0.11 | Sell |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 1.15 | Sell |
| ADX (14) | 18.22 | Neutral |
| ATR (14) | 0.07 | Info |
The 30-day technical picture is neutral with RSI(14) at 40.
The stock trades near a simple moving average framework, with SMA50 at $1.18 and SMA200 at $14.43. Near-term support sits at $0.995 and resistance at $1.41.
The 30-day price range spans from $0.6964 to $1.74, reflecting a wide intramonth movement while sentiment remains labeled NEUTRAL.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.80 | $1.15 | $1.53 | 0% | Neutral | |
| $0.7508 | $1.04 | $1.57 | -9% | Neutral | |
| $0.6078 | $0.8962 | $1.43 | -22% | Bearish | |
| $0.7786 | $1.21 | $2.03 | +5% | Neutral | |
| $0.9201 | $1.50 | $2.61 | +30% | Bullish | |
| $0.8738 | $1.48 | $2.68 | +29% | Bullish | |
| $0.7501 | $1.33 | $2.47 | +16% | Neutral | |
| $0.6453 | $1.19 | $2.27 | +4% | Neutral | |
| $0.6748 | $1.30 | $2.54 | +13% | Neutral | |
| $0.6857 | $1.37 | $2.74 | +19% | Neutral | |
| $0.7433 | $1.65 | $3.63 | +44% | Bullish | |
| $1.71 | $3.80 | $8.74 | +231% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.80 | $1.15 | $1.37 | +0.00% |
| June 2026 | $0.9963 | $1.19 | $1.48 | +3.90% |
| July 2026 | $0.9762 | $1.19 | $1.52 | -0.35% |
| August 2026 | $0.9006 | $1.11 | $1.45 | -6.51% |
| September 2026 | $0.9021 | $1.13 | $1.49 | +1.28% |
| October 2026 | $0.9501 | $1.20 | $1.61 | +6.40% |
| November 2026 | $0.9188 | $1.17 | $1.59 | -2.42% |
| December 2026 | $0.8666 | $1.11 | $1.53 | -4.86% |
Click any year to see its month-by-month QNCX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect QNCX to range from $0.80 to $1.53 through 2026. The $1.15 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The QNCX price prediction for 2027 points to an average of $1.04 (low $0.7508, high $1.57) — a potential decline of -9% on today's $1.15. Price action looks broadly range-bound.
In 2028, QNCX is projected to trade between $0.6078 and $1.43, averaging $0.8962 — a potential decline of -22% from today's $1.15. That is -14% versus the projected 2027 average. Expect choppier, lower action through this leg of the cycle.
Quince Therapeutics, Inc.'s 2029 outlook centres on $1.21, within a $0.7786 to $2.03 range. That is up +35% on the projected 2028 average. That marks a +5% change versus current levels. Price action looks broadly range-bound.
By 2030, QNCX could reach as high as $2.61, with a base case around $1.50 and support toward $0.9201 — roughly +30% from $1.15. Buyers look set to stay in control over this stretch.
Expect QNCX to range from $0.8738 to $2.68 through 2031. The $1.48 average target implies a +29% move from current prices. That is -1% versus the projected 2030 average. Momentum favours further upside here.
The QNCX price prediction for 2032 points to an average of $1.33 (low $0.7501, high $2.47) — a potential gain of +16% on today's $1.15. A consolidation phase looks the most probable path here.
In 2033, QNCX is projected to trade between $0.6453 and $2.27, averaging $1.19 — a potential gain of +4% from today's $1.15. That is -10% versus the projected 2032 average. Price action looks broadly range-bound.
Quince Therapeutics, Inc.'s 2034 outlook centres on $1.30, within a $0.6748 to $2.54 range. That is up +9% on the projected 2033 average. That marks a +13% change versus current levels. A consolidation phase looks the most probable path here.
By 2035, QNCX could reach as high as $2.74, with a base case around $1.37 and support toward $0.6857 — roughly +19% from $1.15. Price action looks broadly range-bound.
Expect QNCX to range from $0.7433 to $3.63 through 2040. The $1.65 average target implies a +44% move from current prices. That is up +21% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The QNCX price prediction for 2050 points to an average of $3.80 (low $1.71, high $8.74) — a potential gain of +231% on today's $1.15. Momentum favours further upside here.
Investing $1,000 in QNCX today (≈ 869.565217 QNCX) could be worth
$3,305.59
+$2,305.59 (+231%) by 2050 · US Dollar
Based on the average projected QNCX price of $3.8 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in QNCXwould be worth at today's price.
$1,000 invested in QNCX on May 27, 2025 (≈ 98.039218 QNCX) would be worth
$112.75
-$887.25 (-88.7%) today · 0.11× · US Dollar
Based on a QNCX entry price of $10.2 vs. today's $1.15.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.08 | $1,064.81 | +6.5% |
| 1 month ago | $1.29 | $891.47 | -10.9% |
| 3 months ago | $1.39 | $827.34 | -17.3% |
| 6 months ago | $36.5 | $31.51 | -96.8% |
| 1 year ago | $10.2 | $112.75 | -88.7% |
| All time (5.0y) ago | $411.9 | $2.79 | -99.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our QNCX forecast.
Our base-case forecast reaches $2.30 around 2050.
Implied market cap at $2.30: $44.99M
2026 shows a flat start with a min of $0.80, an average of $1.10 and a max of $1.46, with ROI of 0% and neutral sentiment. The following year 2027 carries a min of $0.7228, an average of $1.01, a max of $1.51 and an ROI of -8.6% with neutral sentiment. 2028 shows a min of $0.5711, an average of $0.8427, a max of $1.35 and an ROI of -23.4% with bearish sentiment.
From 2030 onward, the forecast turns progressively more bullish: 2030 min $0.8895, average $1.45, max $2.53 with ROI 31.6% and bullish sentiment; 2031 min $0.8224, average $1.40, max $2.52 with ROI 27.1% and bullish sentiment; 2032 min $0.7186, average $1.27, max $2.37 with ROI 15.8% and neutral sentiment; 2033 min $0.6247, average $1.15, max $2.20 with ROI 4.9% and neutral sentiment; 2034 min $0.6365, average $1.22, max $2.39 with ROI 11.1% and neutral sentiment; 2035 min $0.66, average $1.32, max $2.64 with ROI 19.8% and neutral sentiment.
The long‑range horizon remains bullish: 2040 min $0.7013, average $1.56, max $3.43 with ROI 41.7% and bullish sentiment; 2050 min $1.64, average $3.65, max $8.39 with ROI 231.8% and bullish sentiment. These figures are estimates and depend on numerous factors including market conditions and clinical outcomes.
Tap a question to reveal the answer.
2030 forecast shows an avg price of $1.45, with a min of $0.8895 and a max of $2.53, and a projected ROI of 31.6% with bullish sentiment.
The forecast indicates a mixed near-term path (2027 ROI -8.6%; 2028 ROI -23.4%), but a longer-term bullish outlook (2030 avg $1.45; 2050 avg $3.65; max $8.39). These are estimates, not guarantees.
Yes. The 2050 forecast lists a max of $8.39 with a bullish sentiment.
The 30-day range is from a low of $0.6964 to a high of $1.74.
Current price is $1.10 and market cap is $21.52M.
Quince Therapeutics, Inc. Community Discussion
0Share your Quince Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.